#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=6. HIF and Vascular Diseases
1-1	0-2	6.	quantity	new	_	_
1-2	3-6	HIF	abstract|abstract[3]	new|new[3]	coref|coref|coref|coref	3-5|7-1[54_3]|3-5|7-1[54_3]
1-3	7-10	and	abstract[3]	new[3]	_	_
1-4	11-19	Vascular	abstract[3]|abstract|abstract[5]	new[3]|new|new[5]	coref|coref|coref|coref	3-12[16_5]|19-5|3-12[16_5]|19-5
1-5	20-28	Diseases	abstract[3]|abstract[5]	new[3]|new[5]	_	_

#Text=In vascular pathology , hypoxia is typically the consequence of altered , destroyed or absent blood vessels leading to tissue ischemia .
2-1	29-31	In	_	_	_	_
2-2	32-40	vascular	abstract[6]	new[6]	_	_
2-3	41-50	pathology	abstract[6]	new[6]	_	_
2-4	51-52	,	_	_	_	_
2-5	53-60	hypoxia	abstract	new	coref	2-7[8_0]
2-6	61-63	is	_	_	_	_
2-7	64-73	typically	abstract[8]	giv[8]	coref	4-7[0_8]
2-8	74-77	the	abstract[8]	giv[8]	_	_
2-9	78-89	consequence	abstract[8]	giv[8]	_	_
2-10	90-92	of	abstract[8]	giv[8]	_	_
2-11	93-100	altered	abstract[8]	giv[8]	_	_
2-12	101-102	,	abstract[8]	giv[8]	_	_
2-13	103-112	destroyed	abstract[8]	giv[8]	_	_
2-14	113-115	or	abstract[8]	giv[8]	_	_
2-15	116-122	absent	abstract[8]	giv[8]	_	_
2-16	123-128	blood	abstract[8]|substance|object[10]	giv[8]|new|new[10]	coref|coref	21-23|21-23
2-17	129-136	vessels	abstract[8]|object[10]	giv[8]|new[10]	_	_
2-18	137-144	leading	_	_	_	_
2-19	145-147	to	_	_	_	_
2-20	148-154	tissue	object|abstract[12]	new|new[12]	coref|coref|coref|coref	4-2|4-2[29_12]|4-2|4-2[29_12]
2-21	155-163	ischemia	abstract[12]	new[12]	_	_
2-22	164-165	.	_	_	_	_

#Text=The mechanisms of the HIF response have therefore been studied in ischemic vascular diseases , such as myocardial infarction ( consequence of obstruction of coronary arteries ) or peripheral vascular disease ( PAD , consequence of obstruction of arteries going to the limbs ) .
3-1	166-169	The	abstract[13]	new[13]	_	_
3-2	170-180	mechanisms	abstract[13]	new[13]	_	_
3-3	181-183	of	abstract[13]	new[13]	_	_
3-4	184-187	the	abstract[13]|abstract[15]	new[13]|new[15]	coref	5-19[45_15]
3-5	188-191	HIF	abstract[13]|abstract|abstract[15]	new[13]|giv|new[15]	coref	5-7
3-6	192-200	response	abstract[13]|abstract[15]	new[13]|new[15]	_	_
3-7	201-205	have	_	_	_	_
3-8	206-215	therefore	_	_	_	_
3-9	216-220	been	_	_	_	_
3-10	221-228	studied	_	_	_	_
3-11	229-231	in	_	_	_	_
3-12	232-240	ischemic	abstract[16]	giv[16]	coref	4-21[36_16]
3-13	241-249	vascular	abstract[16]	giv[16]	_	_
3-14	250-258	diseases	abstract[16]	giv[16]	_	_
3-15	259-260	,	abstract[16]	giv[16]	_	_
3-16	261-265	such	abstract[16]	giv[16]	_	_
3-17	266-268	as	abstract[16]	giv[16]	_	_
3-18	269-279	myocardial	abstract[16]|event[17]	giv[16]|new[17]	_	_
3-19	280-290	infarction	abstract[16]|event[17]	giv[16]|new[17]	_	_
3-20	291-292	(	_	_	_	_
3-21	293-304	consequence	abstract[18]	new[18]	_	_
3-22	305-307	of	abstract[18]	new[18]	_	_
3-23	308-319	obstruction	abstract[18]|abstract[19]	new[18]|new[19]	_	_
3-24	320-322	of	abstract[18]|abstract[19]	new[18]|new[19]	_	_
3-25	323-331	coronary	abstract[18]|abstract[19]|abstract|object[21]	new[18]|new[19]|new|new[21]	coref|coref	3-39[0_21]|3-39[0_21]
3-26	332-340	arteries	abstract[18]|abstract[19]|object[21]	new[18]|new[19]|new[21]	_	_
3-27	341-342	)	_	_	_	_
3-28	343-345	or	_	_	_	_
3-29	346-356	peripheral	abstract[22]	new[22]	coref	11-27[83_22]
3-30	357-365	vascular	abstract[22]	new[22]	_	_
3-31	366-373	disease	abstract[22]	new[22]	_	_
3-32	374-375	(	_	_	_	_
3-33	376-379	PAD	abstract	new	_	_
3-34	380-381	,	_	_	_	_
3-35	382-393	consequence	abstract[24]	new[24]	_	_
3-36	394-396	of	abstract[24]	new[24]	_	_
3-37	397-408	obstruction	abstract[24]|object[25]	new[24]|new[25]	_	_
3-38	409-411	of	abstract[24]|object[25]	new[24]|new[25]	_	_
3-39	412-420	arteries	abstract[24]|object[25]|object	new[24]|new[25]|giv	coref	14-9[112_0]
3-40	421-426	going	_	_	_	_
3-41	427-429	to	_	_	_	_
3-42	430-433	the	object[27]	new[27]	_	_
3-43	434-439	limbs	object[27]	new[27]	_	_
3-44	440-441	)	_	_	_	_
3-45	442-443	.	_	_	_	_

#Text=Besides tissue ischemia , mechanisms of hypoxia and ischemia can occur within the vascular wall itself , with implications for diseases such as atherosclerosis , arterial aneurysm , chronic venous insufficiency and thromboembolism .
4-1	444-451	Besides	_	_	_	_
4-2	452-458	tissue	object|abstract[29]	giv|giv[29]	coref|coref|coref|coref	4-9[0_29]|14-7|4-9[0_29]|14-7
4-3	459-467	ischemia	abstract[29]	giv[29]	_	_
4-4	468-469	,	_	_	_	_
4-5	470-480	mechanisms	abstract[30]	new[30]	_	_
4-6	481-483	of	abstract[30]	new[30]	_	_
4-7	484-491	hypoxia	abstract[30]|abstract	new[30]|giv	coref	11-1
4-8	492-495	and	abstract[30]	new[30]	_	_
4-9	496-504	ischemia	abstract[30]|abstract	new[30]|giv	ana	4-16
4-10	505-508	can	_	_	_	_
4-11	509-514	occur	_	_	_	_
4-12	515-521	within	_	_	_	_
4-13	522-525	the	place[33]	new[33]	coref	5-22[46_33]
4-14	526-534	vascular	place[33]	new[33]	_	_
4-15	535-539	wall	place[33]	new[33]	_	_
4-16	540-546	itself	place[33]|abstract	new[33]|giv	_	_
4-17	547-548	,	_	_	_	_
4-18	549-553	with	_	_	_	_
4-19	554-566	implications	abstract[35]	new[35]	_	_
4-20	567-570	for	abstract[35]	new[35]	_	_
4-21	571-579	diseases	abstract[35]|abstract[36]	new[35]|giv[36]	_	_
4-22	580-584	such	abstract[35]|abstract[36]	new[35]|giv[36]	_	_
4-23	585-587	as	abstract[35]|abstract[36]	new[35]|giv[36]	_	_
4-24	588-603	atherosclerosis	abstract[35]|abstract[36]|abstract	new[35]|giv[36]|new	coref	7-3
4-25	604-605	,	abstract[35]|abstract[36]	new[35]|giv[36]	_	_
4-26	606-614	arterial	abstract[35]|abstract[36]|abstract[38]	new[35]|giv[36]|new[38]	_	_
4-27	615-623	aneurysm	abstract[35]|abstract[36]|abstract[38]	new[35]|giv[36]|new[38]	_	_
4-28	624-625	,	abstract[35]|abstract[36]	new[35]|giv[36]	_	_
4-29	626-633	chronic	abstract[35]|abstract[36]|abstract[40]	new[35]|giv[36]|new[40]	_	_
4-30	634-640	venous	abstract[35]|abstract[36]|person|abstract[40]	new[35]|giv[36]|new|new[40]	coref	22-1[156_0]
4-31	641-654	insufficiency	abstract[35]|abstract[36]|abstract[40]	new[35]|giv[36]|new[40]	_	_
4-32	655-658	and	abstract[35]|abstract[36]	new[35]|giv[36]	_	_
4-33	659-674	thromboembolism	abstract[35]|abstract[36]|abstract	new[35]|giv[36]|new	_	_
4-34	675-676	.	_	_	_	_

#Text=There is growing evidence that the HIF pathway is implicated — for better or for worse — in the response of the vascular wall to inadequate oxygenation and/or increased cellular oxygen , a demand secondary to various stresses or injuries .
5-1	677-682	There	_	_	_	_
5-2	683-685	is	_	_	_	_
5-3	686-693	growing	_	_	_	_
5-4	694-702	evidence	abstract[42]	new[42]	_	_
5-5	703-707	that	abstract[42]	new[42]	_	_
5-6	708-711	the	abstract[42]|place[44]	new[42]|new[44]	coref	20-4[144_44]
5-7	712-715	HIF	abstract[42]|abstract|place[44]	new[42]|giv|new[44]	coref	7-1
5-8	716-723	pathway	abstract[42]|place[44]	new[42]|new[44]	_	_
5-9	724-726	is	abstract[42]	new[42]	_	_
5-10	727-737	implicated	abstract[42]	new[42]	_	_
5-11	738-739	—	_	_	_	_
5-12	740-743	for	_	_	_	_
5-13	744-750	better	_	_	_	_
5-14	751-753	or	_	_	_	_
5-15	754-757	for	_	_	_	_
5-16	758-763	worse	_	_	_	_
5-17	764-765	—	_	_	_	_
5-18	766-768	in	_	_	_	_
5-19	769-772	the	abstract[45]	giv[45]	_	_
5-20	773-781	response	abstract[45]	giv[45]	_	_
5-21	782-784	of	abstract[45]	giv[45]	_	_
5-22	785-788	the	abstract[45]|place[46]	giv[45]|giv[46]	coref	8-14[60_46]
5-23	789-797	vascular	abstract[45]|place[46]	giv[45]|giv[46]	_	_
5-24	798-802	wall	abstract[45]|place[46]	giv[45]|giv[46]	_	_
5-25	803-805	to	abstract[45]|place[46]	giv[45]|giv[46]	_	_
5-26	806-816	inadequate	abstract[45]|place[46]|abstract[47]	giv[45]|giv[46]|new[47]	_	_
5-27	817-828	oxygenation	abstract[45]|place[46]|abstract[47]	giv[45]|giv[46]|new[47]	_	_
5-28	829-835	and/or	abstract[45]|place[46]	giv[45]|giv[46]	_	_
5-29	836-845	increased	abstract[45]|place[46]|substance[48]	giv[45]|giv[46]|new[48]	coref	11-8[0_48]
5-30	846-854	cellular	abstract[45]|place[46]|substance[48]	giv[45]|giv[46]|new[48]	_	_
5-31	855-861	oxygen	abstract[45]|place[46]|substance[48]	giv[45]|giv[46]|new[48]	_	_
5-32	862-863	,	_	_	_	_
5-33	864-865	a	abstract[49]	new[49]	coref	11-6[78_49]
5-34	866-872	demand	abstract[49]	new[49]	_	_
5-35	873-882	secondary	abstract[49]	new[49]	_	_
5-36	883-885	to	_	_	_	_
5-37	886-893	various	abstract[50]	new[50]	_	_
5-38	894-902	stresses	abstract[50]	new[50]	_	_
5-39	903-905	or	_	_	_	_
5-40	906-914	injuries	event	new	_	_
5-41	915-916	.	_	_	_	_

#Text=6.1 .
6-1	917-920	6.1	abstract	new	_	_
6-2	921-922	.	_	_	_	_

#Text=HIF and Atherosclerosis
7-1	923-926	HIF	abstract|abstract[54]	giv|giv[54]	coref|coref|coref|coref	17-10|19-1[138_54]|17-10|19-1[138_54]
7-2	927-930	and	abstract[54]	giv[54]	_	_
7-3	931-946	Atherosclerosis	abstract[54]|abstract	giv[54]|giv	coref	8-1

#Text=Atherosclerosis is a condition in which fatty deposits ( plaques ) develop in the arterial wall , leading to stenosis and ultimately to thrombosis of the vessel .
8-1	947-962	Atherosclerosis	abstract	giv	coref	8-3[57_0]
8-2	963-965	is	_	_	_	_
8-3	966-967	a	abstract[57]	giv[57]	_	_
8-4	968-977	condition	abstract[57]	giv[57]	_	_
8-5	978-980	in	_	_	_	_
8-6	981-986	which	_	_	_	_
8-7	987-992	fatty	substance[58]	new[58]	_	_
8-8	993-1001	deposits	substance[58]	new[58]	_	_
8-9	1002-1003	(	_	_	_	_
8-10	1004-1011	plaques	object	new	coref	9-1[64_0]
8-11	1012-1013	)	_	_	_	_
8-12	1014-1021	develop	abstract	new	coref|none	20-8[145_0]|8-12[0_145]
8-13	1022-1024	in	_	_	_	_
8-14	1025-1028	the	place[60]	giv[60]	coref	10-12[0_60]
8-15	1029-1037	arterial	place[60]	giv[60]	_	_
8-16	1038-1042	wall	place[60]	giv[60]	_	_
8-17	1043-1044	,	_	_	_	_
8-18	1045-1052	leading	_	_	_	_
8-19	1053-1055	to	_	_	_	_
8-20	1056-1064	stenosis	event	new	_	_
8-21	1065-1068	and	_	_	_	_
8-22	1069-1079	ultimately	event[62]	new[62]	_	_
8-23	1080-1082	to	event[62]	new[62]	_	_
8-24	1083-1093	thrombosis	event[62]	new[62]	_	_
8-25	1094-1096	of	event[62]	new[62]	_	_
8-26	1097-1100	the	event[62]|object[63]	new[62]|new[63]	coref	24-13[0_63]
8-27	1101-1107	vessel	event[62]|object[63]	new[62]|new[63]	_	_
8-28	1108-1109	.	_	_	_	_

#Text=Atherosclerotic plaques are mainly composed of cholesterol , other lipids , calcium , fibrin and inflammatory cells .
9-1	1110-1125	Atherosclerotic	object[64]	giv[64]	coref	10-5[73_64]
9-2	1126-1133	plaques	object[64]	giv[64]	_	_
9-3	1134-1137	are	_	_	_	_
9-4	1138-1144	mainly	_	_	_	_
9-5	1145-1153	composed	_	_	_	_
9-6	1154-1156	of	_	_	_	_
9-7	1157-1168	cholesterol	substance	new	_	_
9-8	1169-1170	,	_	_	_	_
9-9	1171-1176	other	substance[66]	new[66]	_	_
9-10	1177-1183	lipids	substance[66]	new[66]	_	_
9-11	1184-1185	,	_	_	_	_
9-12	1186-1193	calcium	substance	new	_	_
9-13	1194-1195	,	_	_	_	_
9-14	1196-1202	fibrin	substance	new	_	_
9-15	1203-1206	and	_	_	_	_
9-16	1207-1219	inflammatory	object[69]	new[69]	coref	11-11[79_69]
9-17	1220-1225	cells	object[69]	new[69]	_	_
9-18	1226-1227	.	_	_	_	_

#Text=Oxygen diffusion through space-occupying atherosclerotic plaques could be limited due to wall thickening .
10-1	1228-1234	Oxygen	person|abstract[71]	new|new[71]	_	_
10-2	1235-1244	diffusion	abstract[71]	new[71]	_	_
10-3	1245-1252	through	_	_	_	_
10-4	1253-1268	space-occupying	_	_	_	_
10-5	1269-1284	atherosclerotic	substance|object[73]	new|giv[73]	coref|coref|coref|coref	12-12|12-12[89_73]|12-12|12-12[89_73]
10-6	1285-1292	plaques	object[73]	giv[73]	_	_
10-7	1293-1298	could	_	_	_	_
10-8	1299-1301	be	_	_	_	_
10-9	1302-1309	limited	_	_	_	_
10-10	1310-1313	due	_	_	_	_
10-11	1314-1316	to	_	_	_	_
10-12	1317-1321	wall	place|abstract[75]	giv|new[75]	coref|coref	24-12[178_0]|24-12[178_0]
10-13	1322-1332	thickening	abstract[75]	new[75]	_	_
10-14	1333-1334	.	_	_	_	_

#Text=Hypoxia could also originate from the high oxygen demand of metabolically active inflammatory cells , such as macrophage foam cells that play a pivotal role in this disease .
11-1	1335-1342	Hypoxia	abstract	giv	coref	12-22
11-2	1343-1348	could	_	_	_	_
11-3	1349-1353	also	_	_	_	_
11-4	1354-1363	originate	_	_	_	_
11-5	1364-1368	from	_	_	_	_
11-6	1369-1372	the	abstract[78]	giv[78]	_	_
11-7	1373-1377	high	abstract[78]	giv[78]	_	_
11-8	1378-1384	oxygen	substance|abstract[78]	giv|giv[78]	coref	12-35
11-9	1385-1391	demand	abstract[78]	giv[78]	_	_
11-10	1392-1394	of	abstract[78]	giv[78]	_	_
11-11	1395-1408	metabolically	abstract[78]|object[79]	giv[78]|giv[79]	_	_
11-12	1409-1415	active	abstract[78]|object[79]	giv[78]|giv[79]	_	_
11-13	1416-1428	inflammatory	abstract[78]|object[79]	giv[78]|giv[79]	_	_
11-14	1429-1434	cells	abstract[78]|object[79]	giv[78]|giv[79]	_	_
11-15	1435-1436	,	abstract[78]|object[79]	giv[78]|giv[79]	_	_
11-16	1437-1441	such	abstract[78]|object[79]	giv[78]|giv[79]	_	_
11-17	1442-1444	as	abstract[78]|object[79]	giv[78]|giv[79]	_	_
11-18	1445-1455	macrophage	abstract[78]|object[79]|place	giv[78]|giv[79]|new	_	_
11-19	1456-1460	foam	abstract[78]|object[79]|substance	giv[78]|giv[79]|new	_	_
11-20	1461-1466	cells	abstract[78]|object[79]	giv[78]|giv[79]	_	_
11-21	1467-1471	that	_	_	_	_
11-22	1472-1476	play	_	_	_	_
11-23	1477-1478	a	abstract[82]	new[82]	coref	20-1[142_82]
11-24	1479-1486	pivotal	abstract[82]	new[82]	_	_
11-25	1487-1491	role	abstract[82]	new[82]	_	_
11-26	1492-1494	in	abstract[82]	new[82]	_	_
11-27	1495-1499	this	abstract[82]|abstract[83]	new[82]|giv[83]	_	_
11-28	1500-1507	disease	abstract[82]|abstract[83]	new[82]|giv[83]	_	_
11-29	1508-1509	.	_	_	_	_

#Text=Detection of HIF-1α and activation of its target genes occurs in atherosclerotic plaques . During atherogenesis ( plaque build-up ) , hypoxia increases angiogenesis , releases pro-inflammatory mediators , activates MMPs , forms reactive oxygen species , and oxidizes low-density lipoprotein .
12-1	1510-1519	Detection	abstract[84]	new[84]	_	_
12-2	1520-1522	of	abstract[84]	new[84]	_	_
12-3	1523-1529	HIF-1α	abstract[84]|abstract	new[84]|new	coref	14-2
12-4	1530-1533	and	abstract[84]	new[84]	_	_
12-5	1534-1544	activation	abstract[84]|event[86]	new[84]|new[86]	_	_
12-6	1545-1547	of	abstract[84]|event[86]	new[84]|new[86]	_	_
12-7	1548-1551	its	abstract[84]|event[86]|abstract[87]	new[84]|new[86]|new[87]	coref	15-1[117_87]
12-8	1552-1558	target	abstract[84]|event[86]|abstract[87]	new[84]|new[86]|new[87]	_	_
12-9	1559-1564	genes	abstract[84]|event[86]|abstract[87]	new[84]|new[86]|new[87]	_	_
12-10	1565-1571	occurs	_	_	_	_
12-11	1572-1574	in	_	_	_	_
12-12	1575-1590	atherosclerotic	substance|object[89]	giv|giv[89]	coref|coref|coref|coref	13-4|13-4[103_89]|13-4|13-4[103_89]
12-13	1591-1598	plaques	object[89]	giv[89]	_	_
12-14	1599-1600	.	_	_	_	_
12-15	1601-1607	During	_	_	_	_
12-16	1608-1621	atherogenesis	event	new	appos	12-18[92_0]
12-17	1622-1623	(	_	_	_	_
12-18	1624-1630	plaque	object|event[92]	new|giv[92]	coref|coref	13-9|13-9
12-19	1631-1639	build-up	event[92]	giv[92]	_	_
12-20	1640-1641	)	_	_	_	_
12-21	1642-1643	,	_	_	_	_
12-22	1644-1651	hypoxia	event	giv	coref	17-4
12-23	1652-1661	increases	_	_	_	_
12-24	1662-1674	angiogenesis	abstract	new	_	_
12-25	1675-1676	,	_	_	_	_
12-26	1677-1685	releases	event|person[96]	new|new[96]	_	_
12-27	1686-1702	pro-inflammatory	person[96]	new[96]	_	_
12-28	1703-1712	mediators	person[96]	new[96]	_	_
12-29	1713-1714	,	_	_	_	_
12-30	1715-1724	activates	_	_	_	_
12-31	1725-1729	MMPs	object	new	_	_
12-32	1730-1731	,	_	_	_	_
12-33	1732-1737	forms	_	_	_	_
12-34	1738-1746	reactive	abstract[99]	new[99]	_	_
12-35	1747-1753	oxygen	substance|abstract[99]	giv|new[99]	coref	23-16
12-36	1754-1761	species	abstract[99]	new[99]	_	_
12-37	1762-1763	,	_	_	_	_
12-38	1764-1767	and	_	_	_	_
12-39	1768-1776	oxidizes	_	_	_	_
12-40	1777-1788	low-density	substance[100]	new[100]	_	_
12-41	1789-1800	lipoprotein	substance[100]	new[100]	_	_
12-42	1801-1802	.	_	_	_	_

#Text=Necrotic cores within atherosclerotic plaques can lead to plaque instability and thromboembolic complications .
13-1	1803-1811	Necrotic	place[101]	new[101]	coref	14-18[115_101]
13-2	1812-1817	cores	place[101]	new[101]	_	_
13-3	1818-1824	within	place[101]	new[101]	_	_
13-4	1825-1840	atherosclerotic	place[101]|substance|object[103]	new[101]|giv|giv[103]	coref|coref|coref|coref	14-9|17-16[130_103]|14-9|17-16[130_103]
13-5	1841-1848	plaques	place[101]|object[103]	new[101]|giv[103]	_	_
13-6	1849-1852	can	_	_	_	_
13-7	1853-1857	lead	_	_	_	_
13-8	1858-1860	to	_	_	_	_
13-9	1861-1867	plaque	object|abstract[105]	giv|new[105]	coref|coref|coref|coref	15-17|15-17[121_105]|15-17|15-17[121_105]
13-10	1868-1879	instability	abstract[105]	new[105]	_	_
13-11	1880-1883	and	_	_	_	_
13-12	1884-1898	thromboembolic	person|event[107]	new|new[107]	_	_
13-13	1899-1912	complications	event[107]	new[107]	_	_
13-14	1913-1914	.	_	_	_	_

#Text=The HIF-1α protein is found in tissue surrounding atherosclerotic arteries , inflammatory macrophages and arterial SMCs around these necrotic cores .
14-1	1915-1918	The	substance[109]	new[109]	_	_
14-2	1919-1925	HIF-1α	object|substance[109]	giv|new[109]	coref	25-11
14-3	1926-1933	protein	substance[109]	new[109]	_	_
14-4	1934-1936	is	_	_	_	_
14-5	1937-1942	found	_	_	_	_
14-6	1943-1945	in	_	_	_	_
14-7	1946-1952	tissue	object	giv	_	_
14-8	1953-1964	surrounding	_	_	_	_
14-9	1965-1980	atherosclerotic	abstract|object[112]	giv|giv[112]	coref|coref	21-2|21-2
14-10	1981-1989	arteries	object[112]	giv[112]	_	_
14-11	1990-1991	,	object[112]	giv[112]	_	_
14-12	1992-2004	inflammatory	object[112]|object[113]	giv[112]|new[113]	coref	16-9[125_113]
14-13	2005-2016	macrophages	object[112]|object[113]	giv[112]|new[113]	_	_
14-14	2017-2020	and	object[112]	giv[112]	_	_
14-15	2021-2029	arterial	object[112]|place[114]	giv[112]|new[114]	_	_
14-16	2030-2034	SMCs	object[112]|place[114]	giv[112]|new[114]	_	_
14-17	2035-2041	around	object[112]|place[114]	giv[112]|new[114]	_	_
14-18	2042-2047	these	object[112]|place[114]|place[115]	giv[112]|new[114]|giv[115]	_	_
14-19	2048-2056	necrotic	object[112]|place[114]|place[115]	giv[112]|new[114]|giv[115]	_	_
14-20	2057-2062	cores	object[112]|place[114]|place[115]	giv[112]|new[114]|giv[115]	_	_
14-21	2063-2064	.	_	_	_	_

#Text=Proangiogenic HIF-target genes , such as VEGF-A , are responsible for intra-plaque neoangiogenesis , contributing to plaque instability .
15-1	2065-2078	Proangiogenic	abstract[117]	giv[117]	_	_
15-2	2079-2089	HIF-target	abstract|abstract[117]	new|giv[117]	_	_
15-3	2090-2095	genes	abstract[117]	giv[117]	_	_
15-4	2096-2097	,	abstract[117]	giv[117]	_	_
15-5	2098-2102	such	abstract[117]	giv[117]	_	_
15-6	2103-2105	as	abstract[117]	giv[117]	_	_
15-7	2106-2112	VEGF-A	abstract[117]|substance	giv[117]|new	_	_
15-8	2113-2114	,	_	_	_	_
15-9	2115-2118	are	_	_	_	_
15-10	2119-2130	responsible	_	_	_	_
15-11	2131-2134	for	_	_	_	_
15-12	2135-2147	intra-plaque	abstract[119]	new[119]	_	_
15-13	2148-2163	neoangiogenesis	abstract[119]	new[119]	_	_
15-14	2164-2165	,	_	_	_	_
15-15	2166-2178	contributing	_	_	_	_
15-16	2179-2181	to	_	_	_	_
15-17	2182-2188	plaque	object|abstract[121]	giv|giv[121]	coref|coref	17-18|17-18
15-18	2189-2200	instability	abstract[121]	giv[121]	_	_
15-19	2201-2202	.	_	_	_	_

#Text=HIF-1 activity also alters the lipid metabolism of macrophages and vascular SMC .
16-1	2203-2208	HIF-1	abstract[122]	new[122]	_	_
16-2	2209-2217	activity	abstract[122]	new[122]	_	_
16-3	2218-2222	also	_	_	_	_
16-4	2223-2229	alters	_	_	_	_
16-5	2230-2233	the	abstract[124]	new[124]	coref	32-24[267_124]
16-6	2234-2239	lipid	object|abstract[124]	new|new[124]	_	_
16-7	2240-2250	metabolism	abstract[124]	new[124]	_	_
16-8	2251-2253	of	abstract[124]	new[124]	_	_
16-9	2254-2265	macrophages	abstract[124]|object[125]	new[124]|giv[125]	coref	17-18[132_125]
16-10	2266-2269	and	abstract[124]|object[125]	new[124]|giv[125]	_	_
16-11	2270-2278	vascular	abstract[124]|object[125]|object[126]	new[124]|giv[125]|new[126]	_	_
16-12	2279-2282	SMC	abstract[124]|object[125]|object[126]	new[124]|giv[125]|new[126]	_	_
16-13	2283-2284	.	_	_	_	_

#Text=Finally , besides hypoxia , several non-hypoxic stimuli of HIF have also been found in plaques and plaque macrophages , such as inflammation , ROS , vasoactive and thrombotic factors .
17-1	2285-2292	Finally	_	_	_	_
17-2	2293-2294	,	_	_	_	_
17-3	2295-2302	besides	_	_	_	_
17-4	2303-2310	hypoxia	abstract	giv	coref	24-9[176_0]
17-5	2311-2312	,	_	_	_	_
17-6	2313-2320	several	abstract[128]	new[128]	_	_
17-7	2321-2332	non-hypoxic	abstract[128]	new[128]	_	_
17-8	2333-2340	stimuli	abstract[128]	new[128]	_	_
17-9	2341-2343	of	abstract[128]	new[128]	_	_
17-10	2344-2347	HIF	abstract[128]|abstract	new[128]|giv	coref	19-1
17-11	2348-2352	have	_	_	_	_
17-12	2353-2357	also	_	_	_	_
17-13	2358-2362	been	_	_	_	_
17-14	2363-2368	found	_	_	_	_
17-15	2369-2371	in	_	_	_	_
17-16	2372-2379	plaques	object[130]	giv[130]	_	_
17-17	2380-2383	and	object[130]	giv[130]	_	_
17-18	2384-2390	plaque	object[130]|object|object[132]	giv[130]|giv|giv[132]	_	_
17-19	2391-2402	macrophages	object[130]|object[132]	giv[130]|giv[132]	_	_
17-20	2403-2404	,	object[130]|object[132]	giv[130]|giv[132]	_	_
17-21	2405-2409	such	object[130]|object[132]	giv[130]|giv[132]	_	_
17-22	2410-2412	as	object[130]|object[132]	giv[130]|giv[132]	_	_
17-23	2413-2425	inflammation	object[130]|object[132]|abstract	giv[130]|giv[132]|new	_	_
17-24	2426-2427	,	object[130]|object[132]	giv[130]|giv[132]	_	_
17-25	2428-2431	ROS	object[130]|object[132]|abstract	giv[130]|giv[132]|new	coref	32-16
17-26	2432-2433	,	object[130]|object[132]	giv[130]|giv[132]	_	_
17-27	2434-2444	vasoactive	object[130]|object[132]|abstract[135]	giv[130]|giv[132]|new[135]	_	_
17-28	2445-2448	and	object[130]|object[132]|abstract[135]	giv[130]|giv[132]|new[135]	_	_
17-29	2449-2459	thrombotic	object[130]|object[132]|abstract[135]	giv[130]|giv[132]|new[135]	_	_
17-30	2460-2467	factors	object[130]|object[132]|abstract[135]	giv[130]|giv[132]|new[135]	_	_
17-31	2468-2469	.	_	_	_	_

#Text=6.2 .
18-1	2470-2473	6.2	abstract	new	_	_
18-2	2474-2475	.	_	_	_	_

#Text=HIF and NH in Vascular Grafts
19-1	2476-2479	HIF	abstract|abstract[138]	giv|giv[138]	coref|coref	20-5|20-5
19-2	2480-2483	and	abstract[138]	giv[138]	_	_
19-3	2484-2486	NH	abstract[138]|substance[139]	giv[138]|new[139]	coref	20-11[0_139]
19-4	2487-2489	in	abstract[138]|substance[139]	giv[138]|new[139]	_	_
19-5	2490-2498	Vascular	abstract[138]|substance[139]|abstract|object[141]	giv[138]|new[139]|giv|new[141]	coref|coref	22-6[158_141]|22-6[158_141]
19-6	2499-2505	Grafts	abstract[138]|substance[139]|object[141]	giv[138]|new[139]|new[141]	_	_

#Text=The role of the HIF pathway in the development of NH has also been studied .
20-1	2506-2509	The	abstract[142]	giv[142]	_	_
20-2	2510-2514	role	abstract[142]	giv[142]	_	_
20-3	2515-2517	of	abstract[142]	giv[142]	_	_
20-4	2518-2521	the	abstract[142]|place[144]	giv[142]|giv[144]	coref	26-6[202_144]
20-5	2522-2525	HIF	abstract[142]|abstract|place[144]	giv[142]|giv|giv[144]	coref	26-7
20-6	2526-2533	pathway	abstract[142]|place[144]	giv[142]|giv[144]	_	_
20-7	2534-2536	in	abstract[142]|place[144]	giv[142]|giv[144]	_	_
20-8	2537-2540	the	abstract[142]|place[144]|abstract[145]	giv[142]|giv[144]|new[145]	_	_
20-9	2541-2552	development	abstract[142]|place[144]|abstract[145]	giv[142]|giv[144]|new[145]	_	_
20-10	2553-2555	of	abstract[142]|place[144]|abstract[145]	giv[142]|giv[144]|new[145]	_	_
20-11	2556-2558	NH	abstract[142]|place[144]|abstract[145]|substance	giv[142]|giv[144]|new[145]|giv	coref	22-11
20-12	2559-2562	has	_	_	_	_
20-13	2563-2567	also	_	_	_	_
20-14	2568-2572	been	_	_	_	_
20-15	2573-2580	studied	_	_	_	_
20-16	2581-2582	.	_	_	_	_

#Text=When atherosclerotic lesions occupy a long segment of the artery , surgeons frequently use a graft to bypass the lesion and provide blood to distal tissues .
21-1	2583-2587	When	_	_	_	_
21-2	2588-2603	atherosclerotic	object|object[148]	giv|new[148]	_	_
21-3	2604-2611	lesions	object[148]	new[148]	_	_
21-4	2612-2618	occupy	_	_	_	_
21-5	2619-2620	a	place[149]	new[149]	_	_
21-6	2621-2625	long	place[149]	new[149]	_	_
21-7	2626-2633	segment	place[149]	new[149]	_	_
21-8	2634-2636	of	place[149]	new[149]	_	_
21-9	2637-2640	the	place[149]|place[150]	new[149]|new[150]	_	_
21-10	2641-2647	artery	place[149]|place[150]	new[149]|new[150]	_	_
21-11	2648-2649	,	_	_	_	_
21-12	2650-2658	surgeons	person	new	_	_
21-13	2659-2669	frequently	_	_	_	_
21-14	2670-2673	use	_	_	_	_
21-15	2674-2675	a	object[152]	new[152]	coref	27-4[213_152]
21-16	2676-2681	graft	object[152]	new[152]	_	_
21-17	2682-2684	to	_	_	_	_
21-18	2685-2691	bypass	_	_	_	_
21-19	2692-2695	the	object[153]	new[153]	_	_
21-20	2696-2702	lesion	object[153]	new[153]	_	_
21-21	2703-2706	and	_	_	_	_
21-22	2707-2714	provide	_	_	_	_
21-23	2715-2720	blood	substance	giv	_	_
21-24	2721-2723	to	_	_	_	_
21-25	2724-2730	distal	place[155]	new[155]	_	_
21-26	2731-2738	tissues	place[155]	new[155]	_	_
21-27	2739-2740	.	_	_	_	_

#Text=Either venous or prosthetic , these grafts are prone to NH .
22-1	2741-2747	Either	person[156]	giv[156]	coref	25-29[0_156]
22-2	2748-2754	venous	person[156]	giv[156]	_	_
22-3	2755-2757	or	_	_	_	_
22-4	2758-2768	prosthetic	object	new	_	_
22-5	2769-2770	,	_	_	_	_
22-6	2771-2776	these	object[158]	giv[158]	coref	23-2[161_158]
22-7	2777-2783	grafts	object[158]	giv[158]	_	_
22-8	2784-2787	are	_	_	_	_
22-9	2788-2793	prone	_	_	_	_
22-10	2794-2796	to	_	_	_	_
22-11	2797-2799	NH	abstract	giv	coref	23-22
22-12	2800-2801	.	_	_	_	_

#Text=Although vein grafts and prosthetic grafts are not identical , because of different hemodynamics and oxygen tension , the characteristics of NH in vein grafts are similar to those of NH that form in AVFs .
23-1	2802-2810	Although	_	_	_	_
23-2	2811-2815	vein	plant|object[161]	new|giv[161]	coref|coref|coref|coref	23-24|23-24[169_161]|23-24|23-24[169_161]
23-3	2816-2822	grafts	object[161]	giv[161]	_	_
23-4	2823-2826	and	object[161]	giv[161]	_	_
23-5	2827-2837	prosthetic	object[161]	giv[161]	_	_
23-6	2838-2844	grafts	object[161]	giv[161]	_	_
23-7	2845-2848	are	_	_	_	_
23-8	2849-2852	not	_	_	_	_
23-9	2853-2862	identical	_	_	_	_
23-10	2863-2864	,	_	_	_	_
23-11	2865-2872	because	_	_	_	_
23-12	2873-2875	of	_	_	_	_
23-13	2876-2885	different	abstract[162]|person[163]	new[162]|new[163]	ana|ana	27-1[0_163]|27-1[0_163]
23-14	2886-2898	hemodynamics	abstract[162]|person[163]	new[162]|new[163]	_	_
23-15	2899-2902	and	person[163]	new[163]	_	_
23-16	2903-2909	oxygen	person[163]|substance|abstract[165]	new[163]|giv|new[165]	ana|coref|ana|coref	23-29[170_165]|32-10|23-29[170_165]|32-10
23-17	2910-2917	tension	person[163]|abstract[165]	new[163]|new[165]	_	_
23-18	2918-2919	,	_	_	_	_
23-19	2920-2923	the	abstract[166]	new[166]	_	_
23-20	2924-2939	characteristics	abstract[166]	new[166]	_	_
23-21	2940-2942	of	abstract[166]	new[166]	_	_
23-22	2943-2945	NH	abstract[166]|substance	new[166]|giv	coref	23-31
23-23	2946-2948	in	abstract[166]	new[166]	_	_
23-24	2949-2953	vein	abstract[166]|plant|object[169]	new[166]|giv|giv[169]	coref|coref|coref|coref	24-7[0_169]|27-5|24-7[0_169]|27-5
23-25	2954-2960	grafts	abstract[166]|object[169]	new[166]|giv[169]	_	_
23-26	2961-2964	are	_	_	_	_
23-27	2965-2972	similar	_	_	_	_
23-28	2973-2975	to	_	_	_	_
23-29	2976-2981	those	abstract[170]	giv[170]	_	_
23-30	2982-2984	of	abstract[170]	giv[170]	_	_
23-31	2985-2987	NH	abstract[170]|substance	giv[170]|giv	coref	25-30
23-32	2988-2992	that	_	_	_	_
23-33	2993-2997	form	_	_	_	_
23-34	2998-3000	in	_	_	_	_
23-35	3001-3005	AVFs	abstract	new	_	_
23-36	3006-3007	.	_	_	_	_

#Text=In studies with animal models , grafts showed increased hypoxia within the vessel wall in regions of neointimal hyperplasia .
24-1	3008-3010	In	_	_	_	_
24-2	3011-3018	studies	abstract[173]	new[173]	coref	31-1[246_173]
24-3	3019-3023	with	abstract[173]	new[173]	_	_
24-4	3024-3030	animal	abstract[173]|abstract[174]	new[173]|new[174]	_	_
24-5	3031-3037	models	abstract[173]|abstract[174]	new[173]|new[174]	_	_
24-6	3038-3039	,	_	_	_	_
24-7	3040-3046	grafts	object	giv	coref	25-20
24-8	3047-3053	showed	_	_	_	_
24-9	3054-3063	increased	abstract[176]	giv[176]	coref	25-26[0_176]
24-10	3064-3071	hypoxia	abstract[176]	giv[176]	_	_
24-11	3072-3078	within	abstract[176]	giv[176]	_	_
24-12	3079-3082	the	abstract[176]|place[178]	giv[176]|giv[178]	coref	31-26[254_178]
24-13	3083-3089	vessel	abstract[176]|object|place[178]	giv[176]|giv|giv[178]	_	_
24-14	3090-3094	wall	abstract[176]|place[178]	giv[176]|giv[178]	_	_
24-15	3095-3097	in	abstract[176]|place[178]	giv[176]|giv[178]	_	_
24-16	3098-3105	regions	abstract[176]|place[178]|place[179]	giv[176]|giv[178]|new[179]	_	_
24-17	3106-3108	of	abstract[176]|place[178]|place[179]	giv[176]|giv[178]|new[179]	_	_
24-18	3109-3119	neointimal	abstract[176]|place[178]|place[179]|person|abstract[181]	giv[176]|giv[178]|new[179]|new|new[181]	coref|coref|coref|coref	25-17|25-17[190_181]|25-17|25-17[190_181]
24-19	3120-3131	hyperplasia	abstract[176]|place[178]|place[179]|abstract[181]	giv[176]|giv[178]|new[179]|new[181]	_	_
24-20	3132-3133	.	_	_	_	_

#Text=A study using a porcine model showed an association of HIF-1α expression with the degree of neointimal hyperplasia in grafts , and suggested that reducing hypoxia might inhibit venous NH formation , possibly by reducing the phenotypic switch of fibroblasts to myofibroblasts .
25-1	3134-3135	A	abstract[182]	new[182]	_	_
25-2	3136-3141	study	abstract[182]	new[182]	_	_
25-3	3142-3147	using	_	_	_	_
25-4	3148-3149	a	abstract[184]	new[184]	_	_
25-5	3150-3157	porcine	substance|abstract[184]	new|new[184]	_	_
25-6	3158-3163	model	abstract[184]	new[184]	_	_
25-7	3164-3170	showed	_	_	_	_
25-8	3171-3173	an	abstract[185]	new[185]	_	_
25-9	3174-3185	association	abstract[185]	new[185]	_	_
25-10	3186-3188	of	abstract[185]	new[185]	_	_
25-11	3189-3195	HIF-1α	abstract[185]|abstract|abstract[187]	new[185]|giv|new[187]	coref|coref|coref|coref	29-15[230_0]|29-18[232_187]|29-15[230_0]|29-18[232_187]
25-12	3196-3206	expression	abstract[185]|abstract[187]	new[185]|new[187]	_	_
25-13	3207-3211	with	abstract[185]|abstract[187]	new[185]|new[187]	_	_
25-14	3212-3215	the	abstract[185]|abstract[187]|abstract[188]	new[185]|new[187]|new[188]	_	_
25-15	3216-3222	degree	abstract[185]|abstract[187]|abstract[188]	new[185]|new[187]|new[188]	_	_
25-16	3223-3225	of	abstract[185]|abstract[187]|abstract[188]	new[185]|new[187]|new[188]	_	_
25-17	3226-3236	neointimal	abstract[185]|abstract[187]|abstract[188]|person|abstract[190]	new[185]|new[187]|new[188]|giv|giv[190]	_	_
25-18	3237-3248	hyperplasia	abstract[185]|abstract[187]|abstract[188]|abstract[190]	new[185]|new[187]|new[188]|giv[190]	_	_
25-19	3249-3251	in	abstract[185]|abstract[187]|abstract[188]|abstract[190]	new[185]|new[187]|new[188]|giv[190]	_	_
25-20	3252-3258	grafts	abstract[185]|abstract[187]|abstract[188]|abstract[190]|object	new[185]|new[187]|new[188]|giv[190]|giv	_	_
25-21	3259-3260	,	_	_	_	_
25-22	3261-3264	and	_	_	_	_
25-23	3265-3274	suggested	_	_	_	_
25-24	3275-3279	that	_	_	_	_
25-25	3280-3288	reducing	_	_	_	_
25-26	3289-3296	hypoxia	abstract	giv	coref	31-29
25-27	3297-3302	might	_	_	_	_
25-28	3303-3310	inhibit	_	_	_	_
25-29	3311-3317	venous	person|abstract[195]	giv|new[195]	coref|coref	26-13[204_195]|26-13[204_195]
25-30	3318-3320	NH	object|abstract[195]	giv|new[195]	coref	26-13
25-31	3321-3330	formation	abstract[195]	new[195]	_	_
25-32	3331-3332	,	_	_	_	_
25-33	3333-3341	possibly	_	_	_	_
25-34	3342-3344	by	_	_	_	_
25-35	3345-3353	reducing	_	_	_	_
25-36	3354-3357	the	object[197]	new[197]	_	_
25-37	3358-3368	phenotypic	abstract|object[197]	new|new[197]	_	_
25-38	3369-3375	switch	object[197]	new[197]	_	_
25-39	3376-3378	of	object[197]	new[197]	_	_
25-40	3379-3390	fibroblasts	object[197]|object[198]	new[197]|new[198]	_	_
25-41	3391-3393	to	object[197]|object[198]	new[197]|new[198]	_	_
25-42	3394-3408	myofibroblasts	object[197]|object[198]|object	new[197]|new[198]|new	_	_
25-43	3409-3410	.	_	_	_	_

#Text=Paradoxically , increased activation of the HIF pathway may also protect against NH formation . Nakao et al. studied the role of carbon monoxide , a physiologically important vasodilator that acts via cyclic guanosine monophosphate , in the formation of NH .
26-1	3411-3424	Paradoxically	_	_	_	_
26-2	3425-3426	,	_	_	_	_
26-3	3427-3436	increased	abstract[200]	new[200]	_	_
26-4	3437-3447	activation	abstract[200]	new[200]	_	_
26-5	3448-3450	of	abstract[200]	new[200]	_	_
26-6	3451-3454	the	abstract[200]|place[202]	new[200]|giv[202]	coref	30-33[245_202]
26-7	3455-3458	HIF	abstract[200]|abstract|place[202]	new[200]|giv|giv[202]	coref	30-34
26-8	3459-3466	pathway	abstract[200]|place[202]	new[200]|giv[202]	_	_
26-9	3467-3470	may	_	_	_	_
26-10	3471-3475	also	_	_	_	_
26-11	3476-3483	protect	_	_	_	_
26-12	3484-3491	against	_	_	_	_
26-13	3492-3494	NH	substance|abstract[204]	giv|giv[204]	coref|coref|coref|coref	26-38[209_204]|26-41|26-38[209_204]|26-41
26-14	3495-3504	formation	abstract[204]	giv[204]	_	_
26-15	3505-3506	.	_	_	_	_
26-16	3507-3512	Nakao	person	new	_	_
26-17	3513-3515	et	_	_	_	_
26-18	3516-3519	al.	_	_	_	_
26-19	3520-3527	studied	_	_	_	_
26-20	3528-3531	the	abstract[206]	new[206]	_	_
26-21	3532-3536	role	abstract[206]	new[206]	_	_
26-22	3537-3539	of	abstract[206]	new[206]	_	_
26-23	3540-3546	carbon	abstract[206]|substance[207]	new[206]|new[207]	appos	26-26[208_207]
26-24	3547-3555	monoxide	abstract[206]|substance[207]	new[206]|new[207]	_	_
26-25	3556-3557	,	_	_	_	_
26-26	3558-3559	a	substance[208]	giv[208]	coref	28-11[222_208]
26-27	3560-3575	physiologically	substance[208]	giv[208]	_	_
26-28	3576-3585	important	substance[208]	giv[208]	_	_
26-29	3586-3597	vasodilator	substance[208]	giv[208]	_	_
26-30	3598-3602	that	_	_	_	_
26-31	3603-3607	acts	_	_	_	_
26-32	3608-3611	via	_	_	_	_
26-33	3612-3618	cyclic	_	_	_	_
26-34	3619-3628	guanosine	_	_	_	_
26-35	3629-3642	monophosphate	_	_	_	_
26-36	3643-3644	,	_	_	_	_
26-37	3645-3647	in	_	_	_	_
26-38	3648-3651	the	abstract[209]	giv[209]	coref	29-8[229_209]
26-39	3652-3661	formation	abstract[209]	giv[209]	_	_
26-40	3662-3664	of	abstract[209]	giv[209]	_	_
26-41	3665-3667	NH	abstract[209]|substance	giv[209]|giv	coref	27-13[215_0]
26-42	3668-3669	.	_	_	_	_

#Text=They showed that a vein graft placed immediately after harvest led to less NH than if the graft was rinsed with lactated Ringer for 2 h prior to surgical placement .
27-1	3670-3674	They	person	giv	_	_
27-2	3675-3681	showed	_	_	_	_
27-3	3682-3686	that	_	_	_	_
27-4	3687-3688	a	object[213]	giv[213]	coref	27-17[216_213]
27-5	3689-3693	vein	plant|object[213]	giv|giv[213]	coref	31-14
27-6	3694-3699	graft	object[213]	giv[213]	_	_
27-7	3700-3706	placed	_	_	_	_
27-8	3707-3718	immediately	_	_	_	_
27-9	3719-3724	after	_	_	_	_
27-10	3725-3732	harvest	event	new	_	_
27-11	3733-3736	led	_	_	_	_
27-12	3737-3739	to	_	_	_	_
27-13	3740-3744	less	substance[215]	giv[215]	coref	28-17[0_215]
27-14	3745-3747	NH	substance[215]	giv[215]	_	_
27-15	3748-3752	than	_	_	_	_
27-16	3753-3755	if	_	_	_	_
27-17	3756-3759	the	object[216]	giv[216]	coref	31-15[0_216]
27-18	3760-3765	graft	object[216]	giv[216]	_	_
27-19	3766-3769	was	_	_	_	_
27-20	3770-3776	rinsed	_	_	_	_
27-21	3777-3781	with	_	_	_	_
27-22	3782-3790	lactated	person[217]	new[217]	coref	28-6[0_217]
27-23	3791-3797	Ringer	person[217]	new[217]	_	_
27-24	3798-3801	for	person[217]	new[217]	_	_
27-25	3802-3803	2	person[217]|time[218]	new[217]|new[218]	_	_
27-26	3804-3805	h	person[217]|time[218]	new[217]|new[218]	_	_
27-27	3806-3811	prior	_	_	_	_
27-28	3812-3814	to	_	_	_	_
27-29	3815-3823	surgical	event[219]	new[219]	_	_
27-30	3824-3833	placement	event[219]	new[219]	_	_
27-31	3834-3835	.	_	_	_	_

#Text=However , if the lactated Ringer solution was saturated with carbon monoxide , it significantly inhibited NH compared to the untreated control .
28-1	3836-3843	However	_	_	_	_
28-2	3844-3845	,	_	_	_	_
28-3	3846-3848	if	_	_	_	_
28-4	3849-3852	the	substance[221]	new[221]	_	_
28-5	3853-3861	lactated	substance[221]	new[221]	_	_
28-6	3862-3868	Ringer	person|substance[221]	giv|new[221]	_	_
28-7	3869-3877	solution	substance[221]	new[221]	_	_
28-8	3878-3881	was	_	_	_	_
28-9	3882-3891	saturated	_	_	_	_
28-10	3892-3896	with	_	_	_	_
28-11	3897-3903	carbon	substance[222]	giv[222]	ana	28-14[0_222]
28-12	3904-3912	monoxide	substance[222]	giv[222]	_	_
28-13	3913-3914	,	_	_	_	_
28-14	3915-3917	it	substance	giv	coref	29-4[227_0]
28-15	3918-3931	significantly	_	_	_	_
28-16	3932-3941	inhibited	_	_	_	_
28-17	3942-3944	NH	substance	giv	coref	29-8
28-18	3945-3953	compared	_	_	_	_
28-19	3954-3956	to	_	_	_	_
28-20	3957-3960	the	substance[225]	new[225]	_	_
28-21	3961-3970	untreated	substance[225]	new[225]	_	_
28-22	3971-3978	control	substance[225]	new[225]	_	_
28-23	3979-3980	.	_	_	_	_

#Text=The effects of carbon monoxide in inhibiting NH formation seemed to be associated with increased HIF-1α and VEGF expression a few hours after grafting .
29-1	3981-3984	The	abstract[226]	new[226]	coref	30-25[242_226]
29-2	3985-3992	effects	abstract[226]	new[226]	_	_
29-3	3993-3995	of	abstract[226]	new[226]	_	_
29-4	3996-4002	carbon	abstract[226]|substance[227]	new[226]|giv[227]	coref	32-1[259_227]
29-5	4003-4011	monoxide	abstract[226]|substance[227]	new[226]|giv[227]	_	_
29-6	4012-4014	in	_	_	_	_
29-7	4015-4025	inhibiting	_	_	_	_
29-8	4026-4028	NH	substance|abstract[229]	giv|giv[229]	coref|coref	31-14[250_0]|31-14[250_0]
29-9	4029-4038	formation	abstract[229]	giv[229]	_	_
29-10	4039-4045	seemed	_	_	_	_
29-11	4046-4048	to	_	_	_	_
29-12	4049-4051	be	_	_	_	_
29-13	4052-4062	associated	_	_	_	_
29-14	4063-4067	with	_	_	_	_
29-15	4068-4077	increased	abstract[230]	giv[230]	coref	30-18[0_230]
29-16	4078-4084	HIF-1α	abstract[230]	giv[230]	_	_
29-17	4085-4088	and	_	_	_	_
29-18	4089-4093	VEGF	person|abstract[232]	new|giv[232]	_	_
29-19	4094-4104	expression	abstract[232]	giv[232]	_	_
29-20	4105-4106	a	time[233]	new[233]	_	_
29-21	4107-4110	few	time[233]	new[233]	_	_
29-22	4111-4116	hours	time[233]	new[233]	_	_
29-23	4117-4122	after	_	_	_	_
29-24	4123-4131	grafting	_	_	_	_
29-25	4132-4133	.	_	_	_	_

#Text=This effect , including the induction of VEGF , was reversed by treatment with YC-1 , a HIF-1α inhibitor , supporting the conclusion that these effects were mediated through the activation of the HIF pathway .
30-1	4134-4138	This	abstract[234]	new[234]	_	_
30-2	4139-4145	effect	abstract[234]	new[234]	_	_
30-3	4146-4147	,	abstract[234]	new[234]	_	_
30-4	4148-4157	including	abstract[234]	new[234]	_	_
30-5	4158-4161	the	abstract[234]|event[235]	new[234]|new[235]	_	_
30-6	4162-4171	induction	abstract[234]|event[235]	new[234]|new[235]	_	_
30-7	4172-4174	of	abstract[234]|event[235]	new[234]|new[235]	_	_
30-8	4175-4179	VEGF	abstract[234]|event[235]|substance	new[234]|new[235]|new	_	_
30-9	4180-4181	,	_	_	_	_
30-10	4182-4185	was	_	_	_	_
30-11	4186-4194	reversed	_	_	_	_
30-12	4195-4197	by	_	_	_	_
30-13	4198-4207	treatment	event[237]	new[237]	_	_
30-14	4208-4212	with	event[237]	new[237]	_	_
30-15	4213-4217	YC-1	event[237]|substance	new[237]|new	_	_
30-16	4218-4219	,	_	_	_	_
30-17	4220-4221	a	object[240]	new[240]	_	_
30-18	4222-4228	HIF-1α	abstract|object[240]	giv|new[240]	_	_
30-19	4229-4238	inhibitor	object[240]	new[240]	_	_
30-20	4239-4240	,	_	_	_	_
30-21	4241-4251	supporting	_	_	_	_
30-22	4252-4255	the	abstract[241]	new[241]	_	_
30-23	4256-4266	conclusion	abstract[241]	new[241]	_	_
30-24	4267-4271	that	abstract[241]	new[241]	_	_
30-25	4272-4277	these	abstract[241]|abstract[242]	new[241]|giv[242]	coref	32-6[261_242]
30-26	4278-4285	effects	abstract[241]|abstract[242]	new[241]|giv[242]	_	_
30-27	4286-4290	were	abstract[241]	new[241]	_	_
30-28	4291-4299	mediated	abstract[241]	new[241]	_	_
30-29	4300-4307	through	_	_	_	_
30-30	4308-4311	the	event[243]	new[243]	_	_
30-31	4312-4322	activation	event[243]	new[243]	_	_
30-32	4323-4325	of	event[243]	new[243]	_	_
30-33	4326-4329	the	event[243]|place[245]	new[243]|giv[245]	coref	31-21[253_245]
30-34	4330-4333	HIF	event[243]|abstract|place[245]	new[243]|giv|giv[245]	coref	31-22
30-35	4334-4341	pathway	event[243]|place[245]	new[243]|giv[245]	_	_
30-36	4342-4343	.	_	_	_	_

#Text=These apparently contradictory studies suggest that , at least in the setting of vein graft NH , transient activation of the HIF pathway may protect the wall from hypoxia , whereas chronic activation may maintain the ongoing NH process .
31-1	4344-4349	These	abstract[246]	giv[246]	_	_
31-2	4350-4360	apparently	abstract[246]	giv[246]	_	_
31-3	4361-4374	contradictory	abstract[246]	giv[246]	_	_
31-4	4375-4382	studies	abstract[246]	giv[246]	_	_
31-5	4383-4390	suggest	_	_	_	_
31-6	4391-4395	that	_	_	_	_
31-7	4396-4397	,	_	_	_	_
31-8	4398-4400	at	abstract[247]	new[247]	_	_
31-9	4401-4406	least	abstract[247]	new[247]	_	_
31-10	4407-4409	in	abstract[247]	new[247]	_	_
31-11	4410-4413	the	abstract[247]	new[247]	_	_
31-12	4414-4421	setting	abstract[247]	new[247]	_	_
31-13	4422-4424	of	abstract[247]	new[247]	_	_
31-14	4425-4429	vein	abstract[247]|plant|substance[250]	new[247]|giv|giv[250]	coref|coref	31-38[0_250]|31-38[0_250]
31-15	4430-4435	graft	abstract[247]|object|substance[250]	new[247]|giv|giv[250]	_	_
31-16	4436-4438	NH	abstract[247]|substance[250]	new[247]|giv[250]	_	_
31-17	4439-4440	,	_	_	_	_
31-18	4441-4450	transient	abstract[251]	new[251]	coref	31-32[256_251]
31-19	4451-4461	activation	abstract[251]	new[251]	_	_
31-20	4462-4464	of	abstract[251]	new[251]	_	_
31-21	4465-4468	the	abstract[251]|place[253]	new[251]|giv[253]	_	_
31-22	4469-4472	HIF	abstract[251]|abstract|place[253]	new[251]|giv|giv[253]	_	_
31-23	4473-4480	pathway	abstract[251]|place[253]	new[251]|giv[253]	_	_
31-24	4481-4484	may	_	_	_	_
31-25	4485-4492	protect	_	_	_	_
31-26	4493-4496	the	place[254]	giv[254]	coref	32-26[268_254]
31-27	4497-4501	wall	place[254]	giv[254]	_	_
31-28	4502-4506	from	_	_	_	_
31-29	4507-4514	hypoxia	abstract	giv	_	_
31-30	4515-4516	,	_	_	_	_
31-31	4517-4524	whereas	_	_	_	_
31-32	4525-4532	chronic	event[256]	giv[256]	_	_
31-33	4533-4543	activation	event[256]	giv[256]	_	_
31-34	4544-4547	may	_	_	_	_
31-35	4548-4556	maintain	_	_	_	_
31-36	4557-4560	the	abstract[258]	new[258]	_	_
31-37	4561-4568	ongoing	abstract[258]	new[258]	_	_
31-38	4569-4571	NH	substance|abstract[258]	giv|new[258]	_	_
31-39	4572-4579	process	abstract[258]	new[258]	_	_
31-40	4580-4581	.	_	_	_	_

#Text=Carbon monoxide may also display vasoconstrictor effects depending on oxygen and metabolic homeostasis , including ROS production , highlighting the important role of metabolism in the vascular wall .
32-1	4582-4588	Carbon	substance[259]	giv[259]	_	_
32-2	4589-4597	monoxide	substance[259]	giv[259]	_	_
32-3	4598-4601	may	_	_	_	_
32-4	4602-4606	also	_	_	_	_
32-5	4607-4614	display	_	_	_	_
32-6	4615-4630	vasoconstrictor	abstract|abstract[261]	new|giv[261]	_	_
32-7	4631-4638	effects	abstract[261]	giv[261]	_	_
32-8	4639-4648	depending	_	_	_	_
32-9	4649-4651	on	_	_	_	_
32-10	4652-4658	oxygen	substance	giv	_	_
32-11	4659-4662	and	_	_	_	_
32-12	4663-4672	metabolic	abstract[263]	new[263]	_	_
32-13	4673-4684	homeostasis	abstract[263]	new[263]	_	_
32-14	4685-4686	,	abstract[263]	new[263]	_	_
32-15	4687-4696	including	abstract[263]	new[263]	_	_
32-16	4697-4700	ROS	abstract[263]|substance|abstract[265]	new[263]|giv|new[265]	_	_
32-17	4701-4711	production	abstract[263]|abstract[265]	new[263]|new[265]	_	_
32-18	4712-4713	,	_	_	_	_
32-19	4714-4726	highlighting	_	_	_	_
32-20	4727-4730	the	abstract[266]	new[266]	_	_
32-21	4731-4740	important	abstract[266]	new[266]	_	_
32-22	4741-4745	role	abstract[266]	new[266]	_	_
32-23	4746-4748	of	abstract[266]	new[266]	_	_
32-24	4749-4759	metabolism	abstract[266]|abstract[267]	new[266]|giv[267]	_	_
32-25	4760-4762	in	abstract[266]|abstract[267]	new[266]|giv[267]	_	_
32-26	4763-4766	the	abstract[266]|abstract[267]|place[268]	new[266]|giv[267]|giv[268]	_	_
32-27	4767-4775	vascular	abstract[266]|abstract[267]|place[268]	new[266]|giv[267]|giv[268]	_	_
32-28	4776-4780	wall	abstract[266]|abstract[267]|place[268]	new[266]|giv[267]|giv[268]	_	_
32-29	4781-4782	.	_	_	_	_
